Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 8/20 | 0.51 |
| ▸ | MMP2 | P08253 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042958 | 0.88 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL8959587 | 0.86 | KDM4E (0.67) | ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL17226840 | 0.86 | KDM4E (0.56) | ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4041495 | 0.83 | KDM4E (0.63) | ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL22620718 | 0.82 | KDM4E (0.62) | ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL30995161 | 0.81 | KDM4E (0.60) | ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL30995155 | 0.81 | KDM4E (0.60) | ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL29641398 | 0.81 | ALOX15 (0.63) | ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3276358 | 0.81 | ALOX15 (0.63) | ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL9228224 | 0.81 | FGFR1 (0.36) | ALDH1A1KDM4EHPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102692-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-5494928-A | FOR CENTRAL NERVOUS SYSTEM DISORDERS, BLOCKING SEROTONIN RECEPTORS, ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208811-A1 | Aminopyrazole Derivative | FGFR1, FGFR3, FGFR4 | ALDH1A1 919/4885KDM4E 1500/4885HPGD 2535/4885 |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL4I1, CYP3A43 | ALDH1A1 873/4885KDM4E 2063/4885HPGD 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.